MADISON, Wis. — Promega Corporation has reached a settlement with Aobious Inc. to resolve a patent infringement lawsuit involving furimazine and its variants, compounds used in bioluminescence research.
On July 15, 2025, the U.S. District Court for the District of Delaware entered a final Consent Judgment confirming that Aobious infringed four Promega patents. The agreement includes a permanent injunction prohibiting Aobious from further infringement and requires monetary payments to Promega.
“Defending our intellectual property supports our mission of providing high-quality, innovative tools to scientists around the world,” said Kevin Kopish, Promega’s associate director of cell and protein analysis. He added that purchasing reagents through authorized channels ensures quality and funds ongoing innovation.
Furimazine serves as a substrate for NanoLuc luciferase, a Promega enzyme introduced in 2012 that generates exceptionally bright luminescent signals. These signals power assay platforms like NanoBiT and Lumit, which help researchers study proteins in live cells. Promega has licensed several technologies to partners for applications including CRISPR-edited cell lines.
The company continues to invest heavily in research, allocating 13.8% of its revenue to R&D in 2024, above industry averages.
